Home Healthcare IT Tissue Engineering Market Size, Share and Forecast to 2031

Tissue Engineering Market

Tissue Engineering Market Size, Share & Trends Analysis Report By Product Type (Synthetic Scaffold Material, Biologically Derived Scaffold Material, Others), By Applications (Orthopedics and Musculoskeletal, Neurology, Cardiovascular, Skin and Integumentary, Dental, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI54335DR
Study Period 2019-2031 CAGR 14.40%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 3,434.50 Million
Forecast Year 2031 Forecast Year Market Size USD 11526.51 Million
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global tissue engineering industry size was valued at USD 3,434.50 million in 2022. It is projected to reach USD 11,526.51 million by 2031, growing at a CAGR of 14.40% during the forecast period (2023-2031). 

The interdisciplinary field of tissue engineering uses engineering and life science ideas to create biological replacements that restore, maintain, or enhance tissue function. Scaffolds are joined with cells and biomolecules for this procedure. The scaffold is an artificial or organic structure that resembles actual organs. The incidence of chronic diseases and trauma crises increased knowledge of tissue engineering, and prospective pipeline products all indicate a substantial increase in the tissue engineering market throughout the projection period. Additionally, increasing R&D activities would help the market expand as awareness of tissue engineering grows in emerging nations.


  • The biologically derived scaffold material segment is the highest contributor to the market by product.
  • The orthopedics and musculoskeletal segment owns the highest market by application.
  • North America is the major revenue contributor by region.

Market Dynamics

Global Tissue Engineering Market Drivers:

Requirement of Organ Transplants Tissue Engineering in the Future

The growing need for organ transplants worldwide can be met by tissue engineering and regenerative medicine. The development of tissue signaling and vascularization, which would imitate the activities of the original organs, is currently ongoing. To meet the need for organ transplants, there is a better chance of successfully creating complex tissues and entire organs. For instance, tissue engineering regeneration and bioprinting technologies have been used to develop human liver prototypes. Due to the high number of products in the pipeline that are undergoing various clinical trials and are anticipated to be marketed in the future, there is a significant opportunity for the commercialization of tissue-engineered goods.

Technological Developments in Medical Equipment

Technology advancements in medical equipment have revolutionized regenerative medicine and tissue engineering. To supply equipment to the markets for organ regeneration, tissue engineering, and regenerative medicine, several businesses have achieved revolutionary advancements. Furthermore, the commercialization of cutting-edge surgical tools has facilitated the accessibility and simplification of regenerative medicine operations. For instance, the 5210 BioDynamic System and 5270 BioDynamic System from Bose Electroforce provide sterile environments for tissue engineering. Regenerative medicine and tissue engineering are currently on the commercial market thanks to developments in medical automation technology.

Global Tissue Engineering Market Restraint:

Products Made from Tissue Engineering are Quite Expensive

The high cost of tissue engineering limits market expansion. Due to a monopolistic environment and the limited supply of tissue-designed products, the emerging tissue engineering business needs help to overcome difficulties. Because there is less competition among suppliers, these services are more expensive. Organ failures and flaws in the US cost more than 400 billion USD annually, demonstrating the market's potential. Due to the high cost of therapy, there is little demand for tissue engineering in developing nations, which restrains the market's expansion.

Global Tissue Engineering Market Opportunities:

Rising Incidence of Chronic Conditions and Trauma Emergencies

The use of tissue-engineered products has expanded as the frequency of trauma injuries has increased. The market's expansion is also fueled by an increase in the frequency of accidents, burn injuries, and other trauma injuries. According to the Centers for Disease Control and Prevention, 120,859 deaths were attributed to unintentional injuries in the United States in 2016, of which 26,009 were accidental deaths and 33,687 were fatal motor vehicle accidents.

In addition, the prevalence of accident-related trauma cases is rising, accelerating the global uptake of tissue-engineered goods. The tissue-engineered trauma injury products market has seen many businesses increase their market share. The market for tissue-engineered goods is anticipated to expand quickly during the projected period as technology for accidental care units is expected to advance.


Regional Analysis

North America Dominates the Global Market

The global tissue engineering market is divided into four regions: North America, Europe, Asia-Pacific, and LAMEA. 

North America is the major revenue contributor and is expected to grow at a CAGR of 13.35% during the forecast period. Due to the wide availability and accessibility of tissue engineering products and the significant presence of essential businesses and research institutions, North America strongly holds on tissue engineering technologies. The majority of tissue-engineered product producers are based in North America, particularly in the United States. The regional offices of the world's largest tissue engineering companies, including AbbVie Inc., Becton, Dickinson and Company, Organogenesis Holdings, and Zimmer Biomet, are located here. 

Europe is expected to exhibit a CAGR of 14.90% during the forecast period. Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe are the five major European nations taken into account in the report. In 2019, this area held the second-largest market share for tissue engineering worldwide. Due to the region's availability of tissue-engineered products, high demand for tissue-engineered products, and the substantial presence of R&D laboratories and essential enterprises, the tissue engineering market in European countries is anticipated to expand steadily throughout the forecast period. The region's tissue engineering market is expected to increase due to the significant presence of players like B Braun and Tissue Regenix.

China, Japan, Australia, India, South Korea, and the rest of Asia-Pacific are all included in Asia-Pacific. The tissue engineering market has plenty of attractive chances in this area, expected to develop at the fastest rate over the forecast period. The rising demand for advanced healthcare services in developing nations, the development of the R&D sector, and the increased presence of significant players in the region all contribute to the market expansion in this region. Additionally, the industry has developed quickly due to expanding healthcare infrastructure and an emphasis on regenerative medicine. Japan has the most significant impact on the pharmaceutical and biotechnology industries among the Asia-Pacific nations, whereas China has the fastest-growing GDP. 

Africa, the Middle East, and Latin America all makeup LAMEA. It had 3.86% of the worldwide tissue engineering market in 2019 and is anticipated to have sizable growth potential. Due to a paucity of tissue engineering goods, advanced healthcare infrastructure, and qualified medical personnel, the tissue engineering industry in LAMEA is still in its infancy. Due to increased knowledge of tissue engineering products in the region, LAMEA is progressively developing into a valuable tissue engineering market. Most Middle Eastern and Latin American nations, particularly Brazil, Argentina, Mexico, Chile, Saudi Arabia, Turkey, and Uruguay, exhibit sustained and ongoing growth in their investments in science and technology as a share of GDP.


Report Scope

Report Metric Details
By Product Type
  1. Synthetic Scaffold Material
  2. Biologically Derived Scaffold Material
  3. Others
By Applications
  1. Orthopedics and Musculoskeletal
  2. Neurology
  3. Cardiovascular
  4. Skin and Integumentary
  5. Dental
  6. Others
Company Profiles AbbVie Inc. (Allergen Plc.) B. Braun Melsungen AG Becton Dickinson and Company (C. R. BARD, INC.) Integra LifeSciences Organogenesis Holdings Sid Martin Biotech (Axogen) Smith and Nephew Plc. (Osiris Therapeutics) TissueTech Inc. Vericel Corporation Zimmer Biomet Holdings Inc.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global tissue engineering market is segmented by product and application.

Based on product, the global tissue engineering market is bifurcated into synthetic scaffold material, biologically derived scaffold material, and others.

The biologically derived scaffold material segment is the highest contributor to the market and is estimated to exhibit a CAGR of 13.20% during the forecast period. Collagen, alginate, proteoglycans, chitin, agarose, matrigel, and chitosan are only a few biologically derived materials employed in constructing scaffolds. The biologically generated scaffold materials segment is divided into collagen and other types based on the kind. The chemical makeup of biologically generated scaffolding materials for tissue engineering varies. Polypeptides, polysaccharides, polyesters, and inorganic components make up these substances. Chitosan is a fully or partially deacetylated chitin used to manufacture various tissue-engineered products, including vascular grafts, skin, bone, and cartilage. Xenogeneic materials come from diverse kinds of organisms, resulting in different cell types that can be employed in tissue transplants. 

Widespread usage of synthetic biomaterials with specific compositions, microstructures, and long-term repeatability is utilized to replace or repair injured musculoskeletal system components. Synthetic scaffolds are made from synthetic polymers, ceramics, metals, and bioglasses. These biomaterials are employed in treatments including grafting, cementing, dental restorations, and others of a like nature. Depending on their capacity to form a direct link with native tissues after implantation, these materials can be bioinert, bioactive, or bioresorbable. After implantation, bioinert materials, including alumina, zirconia, titanium, and its alloys, do not affect the tissues around them. Bioactive materials like bioglasses and ceramics that directly bind with live tissues are used to correct minor bone flaws and periodontal abnormalities.

Based on application, the global tissue-engineering market is bifurcated into orthopedics and musculoskeletal, neurology, cardiovascular, skin and integumentary, dental, and others.

The orthopedics and musculoskeletal segment owns the highest market and is estimated to exhibit a CAGR of 13.20% during the forecast period. The musculoskeletal and orthopedic systems provide support, stability, and movement. It consists of the skeleton's bones, muscles, cartilage, tendons, ligaments, and connective tissues that hold the body's organs in place and provide support. Tissue engineering is used to repair and replace the meniscus, cartilage tendons, and bone tissues in orthopedic and musculoskeletal procedures. The most potential applications of musculoskeletal tissue engineering are in bone and cartilage repair and replacement. 

Globally, cardiovascular illnesses are the leading cause of death. Because the heart's ability to regenerate is limited, transplantation may be the sole option in some circumstances, albeit having significant drawbacks. Tissue engineering is therefore viewed as the best strategy in cardiology. Cardiac tissue engineering mainly entails cardiac grafts, such as tissues, and the regeneration of tissues without creating side effects like immunogenicity. The most common biomaterials for heart regeneration are polymers, which include synthetic, natural, and combination materials. Polyglycolic acid (PGA), polylactic-l-acid (PLLA), and polylactic glycolic acid (PLGA) polyurethane are examples of synthetic polymers utilized for cardiac tissue engineering.

Tissue-engineered products for treating burns, chronic wounds, and wounds following cosmetic surgery are included in the skin and integumentary sector. The most frequent cause of skin abrasion is thermal damage. In the United States, there are one million hospital emergencies related to thermal injuries yearly. Skin loss can also result from trauma, persistent ulceration, and thermal burns. Doctors face difficulties when treating burn victims. Various skin tissue engineering techniques, such as skin tissue grafting, are used to treat burns. Grafting one's bodily tissue is not an option if the burn damage is more significant than 90%. In these situations, medical professionals attempt to cultivate epidermal tissues in vitro by giving nutrient-rich supplements.

Simple tooth decay too extensive oncologic craniofacial excision are all examples of dental deformities. To maximize the growth of a single tissue, the hybrid organ in dentistry, it is vital to identify suitable scaffolds and cell sources. Regeneration of teeth, oral mucosa, salivary glands, bone, and periodontium are all included in dental tissue engineering. Additionally, this portion considers tissue regeneration for the alveolar bone, periodontal ligament, enamel, dentin, and entire tooth. Additionally, cells must be given the proper spatial and temporal cues to permit growth, differentiation, and the production of an extracellular matrix with an adequate volume and functional integrity to engineer functional tissues.

Applications of tissue engineering in ophthalmology, gastrointestinal disorders, obstetrics, and other soft tissues are included in the others segment. Products from ocular tissue engineering have great potential for treating or repairing ocular tissues. Research has been conducted to provide ground-breaking techniques for treating various eye disorders, including glaucoma, corneal disease, age-related macular degeneration (AMD), and ocular cancer. After transplantation, engineered biomaterials encourage the survival and functional proliferation of neurons. Additionally, the transplantation of stem cells and tissue grafts into the retina is done to help the recipient develop useful neural connections after the transplant.


Market Size By Product Type

Recent Developments

  • May 2022- Quali-Pure HGP 2000, a novel endotoxin-controlled pharmaceutical-grade gelatin especially created for vaccinations and wound healing applications, was introduced by Rousselot, the health brand of Darling Ingredients.
  • February 2022- Opus BA, a synthetic bioactive bone graft product from Orthofix Medical, was approved for use in cervical and lumbar spine fusion surgeries.

Top Key Players

AbbVie Inc. (Allergen Plc.) B. Braun Melsungen AG Becton Dickinson and Company (C. R. BARD, INC.) Integra LifeSciences Organogenesis Holdings Sid Martin Biotech (Axogen) Smith and Nephew Plc. (Osiris Therapeutics) TissueTech Inc. Vericel Corporation Zimmer Biomet Holdings Inc. Others

Frequently Asked Questions (FAQs)

How big is the tissue engineering market?
The global tissue engineering industry was valued at USD 3,434.50 million in 2022. It is projected to reach USD 11,526.51 million by 2031, growing at a CAGR of 14.40% during the forecast period (2023-2031).
Europe has the highest growth rate in the tissue engineering market.
Key verticals adopting the tissue engineering market include: AbbVie Inc. (Allergen Plc.), B. Braun Melsungen AG, Becton, Dickinson, and Company (C. R. BARD, INC.), Integra LifeSciences, Organogenesis Holdings, Sid Martin Biotech (Axogen), Smith and Nephew Plc. (Osiris Therapeutics), TissueTech Inc., Vericel Corporation, and Zimmer Biomet Holdings Inc.
The requirement for organ transplant tissue engineering in the future is the key drivers for the growth of the tissue engineering market.
Products made from tissue engineering are quite expensive is one of the upcoming key trends in the tissue engineering market.

We are featured on :

This website uses cookies to ensure you get the best experience on our website. Privacy Policy